Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Video Vignettes

This video series aims to provide an overview of the latest treatments available for patients with relapsed or refractory mantle cell lymphoma. The series covers recent trial results, potential new therapies, and an analysis of considerations to bear in mind when deciding on treatment options. The series will also include a case study presentation and discussion between panelists. The series will cover:

• Updates on new therapies
• BTK inhibitors
• Case studies

Relapsed/Refractory Mantle Cell Lymphoma—Update on New Therapies

In this video, Dr. John Burke provides a brief overview of relapsed/refractory mantle cell lymphoma. He notes that mantle cell lymphoma is a relatively uncommon subtype of non-Hodgkin’s lymphoma, which is often diagnosed at advanced stages. Dr. Burke explores recent advancements in treating relapsed/refractory mantle cell lymphoma, including BTK inhibitors. He also examines chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma, focusing on patient eligibility, timing of therapy, and overall response rates. Although bispecific antibodies are not yet approved for mantle cell lymphoma, Dr. Burke reviews the results of early-phase trials. Finally, he reviews a novel BCL-2 inhibitor and highlights combination therapies from recent clinical trials, along with an additional overview of adverse effects.

Cancer Buzz Podcasts

Adverse Event Management in Relapsed/Refractory Mantle Cell Lymphoma – [Video Podcast] Ep 48

In this episode, CANCER BUZZ speaks with Karen Fancher, PharmD, BCOP, clinical pharmacy specialist in oncology at University of Pittsburgh – Passavant Hospital, and Victoria Nachar, PharmD, BCOP, clinical pharmacist specialist in ambulatory hematology and adjunct clinical instructor at the University of Michigan, about strategies to address common adverse events experienced by patients with mantle cell lymphoma.

Shared Decision Making in Relapsed/Refractory Mantle Cell Lymphoma – [Video Podcast] Ep 50

In this episode, CANCER BUZZ speaks with Nirav Shah, MD, MSHP, associate professor of medicine at Medical College of Wisconsin and Kirollos Hanna, PharmD, BCOP, PCOP, FACCC, assistant professor of pharmacy at Mayo Clinic and director of pharmacy at Minnesota Oncology, about shared decision making in the management of relapsed or refractory mantle cell lymphoma.

Establishing Goals of Treatment in Relapsed/Refractory Mantle Cell Lymphoma – [Video Podcast] Ep 51

In this episode, CANCER BUZZ speaks with Jeff Sharman, MD, medical director of hematology research, US Oncology, and director of research, Willamette Valley Cancer Institute, about the role of biomarker testing in guiding treatment decisions and how evidence-based management of treatment-related adverse events can serve this patient population.

BTK Inhibitors in Mantle Cell Lymphoma

Dr. Jeff Sharman discusses BTK inhibitors in this video, focusing on progression-free survival and overall survival based on lines of therapy. He reviews findings from clinical studies, including the withdrawal of ibrutinib from the mantle cell lymphoma market. Dr. Sharman also provides an overview of the adverse effects and toxicity profiles for each BTK inhibitor, taking into account comorbidities and prior treatments. Additionally, he covers BTK resistance and non-covalent BTK inhibitors that are being investigated for use in relapsed/refractory mantle cell lymphoma.

Relapsed/Refractory Mantle Cell Lymphoma Case Studies

In a collaborative discussion, Kirollos Hanna, Dr. Jeff Sharman, and Dr. John Burke reviewed patients who have been newly diagnosed with or have relapsed mantle cell lymphoma. Dr. Sharman discussed the expected initial management, as well as the factors that healthcare providers need to consider when treating patients with mantle cell lymphoma. The case studies reviewed included patients of varying ages, extent of disease, and comorbidities. Drs. Sharman and Burke also reviewed the recent clinical trials that were discussed in prior presentations and how to apply those in clinical practice when deciding on the treatment options for patients with mantle cell lymphoma.